Key result
Cardiac autonomic neuropathy is a highly prevalent complication, affecting 17-66% of patients with type 1 diabetes and 31-73% of patients with type 2 diabetes.
Cardiac autonomic neuropathy is a highly prevalent complication in diabetic patients, emphasizing the need for early diagnosis and potential treatment with vitamin and antioxidant therapies.
Cardiac autonomic neuropathy (CAN) is a common and insufficiently diagnosed complication of diabetes mellitus. This is usually due to the fact that the disease runs asymptomatically until the very late stages. The impact of CAN on patients with diabetes can be devastating, because CAN is associated with increased mortality, cardiovascular disease, chronic kidney disease. CAN prevalence: 17-66% in patients with type 1 diabetes and 31–73% in patients with type 2 diabetes. Hyperglycemia, autoimmune reaction, genetic factors, obstructive sleep apnea, and inflammation are the key points in the pathogenesis of neuropathies in diabetes, in particular, CAN. Clinical manifestations of CAN and risk factors of CAN development in patients with diabetes are considered. Early diagnosis of CAN is of vital importance for the success of therapy, as there is an assumption that denervation of cardiovascular system may be reversible if diagnosed soon after its beginning. Antioxidant, vasoactive and vitamin therapy is used in the treatment of CAN. Emphasis is placed on the use of the injection form of Neuromultivitis.
No takes yet. Share an insight, caveat, or question.
Belyaev et al. (2019) conducted a review in Cardiac autonomic neuropathy in diabetes mellitus. Neuromultivitis was evaluated. Cardiac autonomic neuropathy is a highly prevalent complication, affecting 17-66% of patients with type 1 diabetes and 31-73% of patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: